Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
VOYAGE
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
- NCT02152956 ↗
- Terminated
- MacroGenics
- Focused
We haven't built an HCP commentary report on VOYAGE (flotetuzumab in primary induction failure or early relapse AML) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on VOYAGE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
- Phase
- Phase 1/Phase 2
- Status
- Terminated
- Conditions
- AML
- Interventions
- Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off; Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off; Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off; Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off; Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose; Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose; Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose; Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose; Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose; Ruxolitinib; Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose
- Arms
- Cohort 0-a · Experimental
- Cohort 0-b · Experimental
- Cohort 0-c · Experimental
- Cohort 0-d · Experimental
- Cohort 1 · Experimental
- Cohort 2 · Experimental
- Cohort 2a · Experimental
- Cohort 3 · Experimental
- Cohort 6 · Experimental
- Cohort 7 · Experimental
- Cohort 8 · Experimental
- MTD Expansion · Experimental
- MTD expansion with Ruxolitinib · Experimental
- Enrollment
- 244
- Primary outcomes
- Efficacy Based on CR or CRh Rate
- Sponsor
- MacroGenics
- Start
- Jun 9, 2014
- Primary completion
- Jul 5, 2022
- Results posted
- Yes
- Registry record
- NCT02152956 · updated Jan 30, 2024
Publications
linked from the registry- Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, Godwin JE, Arellano ML, Sweet KL, Emadi A, Ravandi F, Erba HP, Byrne M, Michaelis L, Topp MS, Vey N, Ciceri F, Carrabba MG, Paolini S, Huls GA, Jongen-Lavrencic M, Wermke M, Chevallier P, Gyan E, Recher C, Stiff PJ, Pettit KM, Lowenberg B, Church SE, Anderson E, Vadakekolathu J, Santaguida M, Rettig MP, Muth J, Curtis T, Fehr E, Guo K, Zhao J, Bakkacha O, Jacobs K, Tran K, Kaminker P, Kostova M, Bonvini E, Walter RB, Davidson-Moncada JK, Rutella S, DiPersio JF. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021 Feb 11;137(6):751-762. doi: 10.1182/blood.2020007732. PubMed 32929488